medigraphic.com

2016, Number 4

<< Back Next >>

Rev Med MD 2016; 7.8 (4)

Pulse oximetry as a potential tool to detect congenital heart abnormalities in neonates

González-Cantú CA, Angulo-Castellanos E, García-Morales E, López-Hernández RD, Ferraez-Pech MA, Vázquez-Grave DA, Gómez-Arellano AL, Salcedo-Padilla SG, López-Palomar GD, Hernández-Torres LE, Pérez-Díaz CI, Barragán-Sánchez A, Razo-Cervantes JC

Language: Spanish
References: 15
Page: 224-228
PDF size: 756.84 Kb.


ABSTRACT

Introduction. Congenital heart defects are the main cause of infant mortality when compared to other malformations. Among mayor congenital abnormalities, cardiac defects (up to 28%) are the most frequent. The main objective of this study is to evaluate the use of pulse oximetry as a potential tool for early detection of critical heart anomalies.
Material and Methods. With an observational and prospective study we obtained measurements of pre and postductal saturation. Demographic data was collected from neonates admitted to maternal cohabitation area at Hospital Civil de Guadalajara Fray Antonio Alcalde from March 1 to July 1, 2015 with the aim to detect critical cardiac defects.
Results. The sample included 260 newborns, 127 females and 133 males. Epidemiologic profile included gestational age (GA) (X=39+1.4 GA), weight (X= 49.2+1.9 cm), vaginal delivery 144 (55.4%) and cesarean 116 (44.6%), pre and postductal pulse oximetry (X=96% SD 1.7-1.8).
Conclusions. All of the newborns included in this sample were considered as healthy and with no evidence of critical heart abnormalities. We suggest an increase in the sample number in order to detect patients with probabilities of having a congenital heart disease. This way specificity and sensibility of pulse oximetry may be evaluated as a diagnostic test used in routine screening. Pulse oximetry proved to be trustworthy, feasible and cost effective.


REFERENCES

  1. Cervera R, Piette J, Font J, Khamashta MA, Shoenfeld Y, Camps T, et al. Antiphospholipid Syndrome Clinical and Immunologic Manifestations and Patterns of Disease Expression in a Cohort of 1000 patients. Arthritis Rheum 2002;46(4):1019–27.

  2. Pinto-almeida T, Caetano M, Sanches M, Selores M. Cutaneous manifestations of antiphospholipid syndrome: A review of the clinical features, diagnosis and management. Acta Reumatol Port. 2013;10–8.

  3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. England; 2006 Feb;4(2):295–306.

  4. Neill AO, Gatenby PA, Mcgaw B, Painter DM. Widespread cutaneous necrosis associated with cardiolipin antibodies. Journal of the American Academy of Dermatology 1990;356–9.

  5. Amster MS, Conway J, Zeid M, Pincus S. Cutaneous necrosis resulting from protein S deficiency and increased antiphospholipid antibody in a patient with systemic lupus erythematosus. J Am Acad Dermatol. American Academy of Dermatology, Inc.; 1993;29(5 Pt 2):853–7.

  6. Soweid AM, Hajjar RR, Hewan-Lowe KO, Gonzalez EB. Skin necrosis indicating antiphospholipid syndrome in patient with AIDS. South Med J. UNITED STATES; 1995 Jul;88(7):786–8.

  7. Jou I. Case Report Widespread Cutaneous Necrosis Associated with Antiphospholipid Syndrome. Clin Rheumatol. 1996 Jul;15(4):394-8.

  8. Fiehn C, Breitbart A, Germann G. Autologous skin transplantation for widespread cutaneous necrosis in secondary antiphospholipid syndrome. Ann Rheum Dis 2001;60:908–910.

  9. Creamer D, Hunt BJ, Black MM. Widespread cutaneous necrosis occurring in association with the antiphospholipid syndrome: A report of two cases. Br J Dermatol. 2000;142(6):1199–203.

  10. Rossini J, Roverano S, Graf C, Paira S. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol. 2002;8(6):326–31.

  11. DiFrancesco LM, Burkart P, Hoehn JG. A Cutaneous Manifestation of Antiphospholipid Antibody Syndrome. Ann Plast Surg. 2003;51(5):517–22.

  12. Costa R, Fazal S, Kaplan RB, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013;32(SUPPL. 1):79–82.

  13. De Souza A, Capriglione ML, Fernandes J. Necrose cutanea extensa como primeira manifestacao da sindrome antifosfolipidica (SAF) secundaria. Acta Reumatologica Portuguese 2010;35:244-248.

  14. Aghdashi M, Aghdashi M, Rabiepoor M. Cutaneous necrosis of lower extremity as the fi rst manifestation of catastrophic antiphospholipid syndrome. Mod Rheumatol. 2015 May;25(3):490-2.

  15. Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol. ENGLAND; 1989 Mar;120(3):419–29.




2020     |     www.medigraphic.com